![The World Congress on Controversies in Obstetrics, Gynecology and Infertility (COGI). Click here to learn more.]({"type":"image" , "src" : "/sda/112382/JournalAd-COGI2024-Leaderboard.jpg"})
References
- Dilts P V, Jr, Hopkins M P, Chang A E, Cody R L. Rapid growth of leiomyoma in patient receiving tamoxifen. American Journal of Obstetrics and Gynecology 1992; 166: 167–168
- Kang J, Baxi L, Heller D. Tamoxifen-induced growth of leiomyomas. A case report. Journal of Reproductive Medicine 1996; 41: 119–120
- Leo L, Lanza A, Re A, Tessarolo M, Bellino R, Lauricella A, Wierdis T. Leiomyomas in patients receiving tamoxifen. Clinical and Experimental Obstetrics and Gynecology 1994; 21: 94–98
- Lumsden M A, West C P, Hillier H, Baird D T. Estrogenic action of tamoxifen in women treated with luteinizing hormone-releasing hormone agonists (goserelin)–lack of shrinkage of uterine fibroids. Fertility and Sterility 1989; 52: 924–929
- Sadan O, Ginath S, Sofer D, Rotmensch S, Debby A, Glezerman M, , et al. The role of tamoxifen in the treatment of symptomatic uterine leiomyomata – a pilot study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2001; 96: 183–186
- Saynajakangas O, Maiche A G, Liakka K A. Multiple progressive pulmonary leiomyomatous metastases treated with tamoxifen – a case report with a review of the literature. Acta Oncologica 2004; 43: 113–114